Raltegravir potassium saltCAS# 871038-72-1 |
- Atazanavir
Catalog No.:BCC3622
CAS No.:198904-31-3
- HIV-1 integrase inhibitor
Catalog No.:BCC1618
CAS No.:544467-07-4
- Elvitegravir (GS-9137)
Catalog No.:BCC2134
CAS No.:697761-98-1
- BMS-707035
Catalog No.:BCC2133
CAS No.:729607-74-3
- HIV-1 integrase inhibitor 2
Catalog No.:BCC1619
CAS No.:957890-42-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 871038-72-1 | SDF | Download SDF |
PubChem ID | 23668479 | Appearance | Powder |
Formula | C20H20FKN6O5 | M.Wt | 482.51 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | MK 0518 potassium salt | ||
Solubility | H2O : 25 mg/mL (51.81 mM; Need ultrasonic) DMSO : 6 mg/mL (12.43 mM; Need ultrasonic) | ||
Chemical Name | potassium;4-[(4-fluorophenyl)methylcarbamoyl]-1-methyl-2-[2-[(5-methyl-1,3,4-oxadiazole-2-carbonyl)amino]propan-2-yl]-6-oxopyrimidin-5-olate | ||
SMILES | CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)[O-])C(=O)NCC3=CC=C(C=C3)F.[K+] | ||
Standard InChIKey | IFUKBHBISRAZTF-UHFFFAOYSA-M | ||
Standard InChI | InChI=1S/C20H21FN6O5.K/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11;/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30);/q;+1/p-1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Raltegravir (potassium salt) is a potent integrase (IN) inhibitor, used to treat HIV infection.In Vitro:PFV IN carrying the S217H substitution is 10-fold less susceptible to Raltegravir with IC50 of 900 nM. PFV IN displays 10% of WT activity and is inhibited by Raltegravir with an IC50 of 200 nM, indicating a appr twofold decrease in susceptibility to the IN strand transfer inhibitor (INSTI) compared with WT IN. S217Q PFV IN is as sensitive to Raltegravir as the WT enzyme[1]. Raltegravir is metabolized by glucuronidation, not hepatically. Raltegravir has potent in vitro activity against HIV-1, with a 95% inhibitory concentration of 31±20 nM, in human T lymphoid cell cultures. Raltegravir is also active against HIV-2 when Raltegravir is tested in CEMx174 cells, with an IC95 of 6 nM. Raltegravir metabolism occurs primarily through glucuronidation. Drugs that are strong inducers of the glucuronidation enzyme, UGT1A1, significantly reduce Raltegravir concentrations and should not be used. Raltegravir exhibits weak inhibitory effects on hepatic cytochrome P450 activity. Raltegravir does not induce CYP3A4 RNA expression or CYP3A4-dependent testosterone 6-β-hydroxylase activity[2]. Raltegravir cellular permeativity is reduced in the presence of magnesium and calcium[3]. Raltegravir and related HIV-1 integrase (IN) strand transfer inhibitors (INSTIs efficiently block viral replication[4]. In acutely infected human lymphoid CD4+ T-cell lines MT-4 and CEMx174, SIVmac251 replication is efficiently inhibited by Raltegravir, which shows an EC90 in the low nanomolar range[5].In Vivo:Raltegravir induces viro-immunological improvement of nonhuman primates with progressing SIVmac251 infection. One non-human primate shows an undetectable viral load following Raltegravir monotherapy[5]. References: |
Raltegravir potassium salt Dilution Calculator
Raltegravir potassium salt Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.0725 mL | 10.3625 mL | 20.725 mL | 41.4499 mL | 51.8124 mL |
5 mM | 0.4145 mL | 2.0725 mL | 4.145 mL | 8.29 mL | 10.3625 mL |
10 mM | 0.2072 mL | 1.0362 mL | 2.0725 mL | 4.145 mL | 5.1812 mL |
50 mM | 0.0414 mL | 0.2072 mL | 0.4145 mL | 0.829 mL | 1.0362 mL |
100 mM | 0.0207 mL | 0.1036 mL | 0.2072 mL | 0.4145 mL | 0.5181 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Raltegravir potassium salt(MK0518 potassium salt) is a potent integrase (IN) inhibitor, used to treat HIV infection.
- TAK-285
Catalog No.:BCC3860
CAS No.:871026-44-7
- 5-Methoxystrictamine
Catalog No.:BCN4416
CAS No.:870995-64-5
- Neuromedin B (porcine)
Catalog No.:BCC5841
CAS No.:87096-84-2
- 5-Hydroxy-1,7-diphenyl-6-hepten-3-one
Catalog No.:BCN1321
CAS No.:87095-74-7
- Mulberrofuran G
Catalog No.:BCN3693
CAS No.:87085-00-5
- E 2012
Catalog No.:BCC1540
CAS No.:870843-42-8
- MK 0893
Catalog No.:BCC1752
CAS No.:870823-12-4
- Leptomycin B
Catalog No.:BCC7223
CAS No.:87081-35-4
- AC 261066
Catalog No.:BCC7848
CAS No.:870773-76-5
- PAP-1
Catalog No.:BCC1836
CAS No.:870653-45-5
- Euphohelioscopin A
Catalog No.:BCN6501
CAS No.:87064-61-7
- Zeylasteral
Catalog No.:BCN3065
CAS No.:87064-16-2
- TCS 3035
Catalog No.:BCC8036
CAS No.:871085-49-3
- Almorexant
Catalog No.:BCC5122
CAS No.:871224-64-5
- Isoneochamaejasmine A
Catalog No.:BCN3131
CAS No.:871319-96-9
- SC 66
Catalog No.:BCC6160
CAS No.:871361-88-5
- CTEP (RO4956371)
Catalog No.:BCC4599
CAS No.:871362-31-1
- H-1152 dihydrochloride
Catalog No.:BCC1616
CAS No.:871543-07-6
- Schisanlactone A
Catalog No.:BCN3185
CAS No.:87164-31-6
- Trametinib (GSK1120212)
Catalog No.:BCC1282
CAS No.:871700-17-3
- 2-Deacetoxydecinnamoyltaxinine J
Catalog No.:BCN7218
CAS No.:87193-98-4
- WAY 207024 dihydrochloride
Catalog No.:BCC7802
CAS No.:872002-73-8
- Dihydrotanshinone I
Catalog No.:BCN4417
CAS No.:87205-99-0
- K 114
Catalog No.:BCC5984
CAS No.:872201-12-2